Apeloa Pharmaceutical (000739.SZ): The oral suspension of oseltamivir phosphate has obtained a drug registration certificate.

Apeloa Pharmaceutical (000739.SZ) announced that its controlling subsidiary Zhejiang Pu Lu Kangyu Pharmaceutical Co., Ltd. has recently received the "Drug Registration Certificate" issued by the National Medical Products Administration for the Oseltamivir Phosphate for Oral Suspension. The active metabolite of Oseltamivir Phosphate (Oseltamivir carboxylate) is a selective neuraminidase inhibitor for influenza viruses, which can inhibit the neuraminidase activity of influenza A and B viruses, reducing the spread of these viruses by inhibiting their release from infected cells. Oseltamivir Phosphate for Oral Suspension is used for the treatment of influenza A and B in patients aged 2 weeks and older, as well as for the prevention of influenza A and B in individuals aged 1 year and older.